Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France
|
|
- Jesse West
- 5 years ago
- Views:
Transcription
1 Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France
2 LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage Occlusion Procedure
3 AF and Stroke. 3 million in US, 4.5 million in the EU have AF 1. 2/3 of AF population are at high-risk of stroke 1 35% of patients with AF will have a stroke in their lifetime 2. AF responsible for 15-20% of ischemic strokes 1. AF Incidence increases with age % in general population. 0.2% of yrs of age Estimated age-specific AF prevalence % of >60 yrs of age. 10% of > 80 yrs of age Relationship of AF and stroke 2 1. Fuster, et al., ACC/AHA/ESC Practice Guidelines, Circulation. 2006;114: Wolf PA, et al., Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991;22:983 8
4 Warfarin: The cornerstone therapy Adjusted-dose Warfarin agents reduce stroke by 60% 1 Inadequate warfarin usually seen in pts admitted for Stroke 2 (High-risk pts with AF candidates for OAC): Only 29% on therapeutic level for Warfarin dose Of the remaining: 10% were sub-therapeutic, 31% were on Antiplatelet, 29% no therapy was prescribed Warfarin is CI in 14-47% of pts at risk of stroke 4 It is not prescribed in 21% of the indicated patients 3 Less than 50% of pts eligible are being treated with warfarin due to tolerance or non-compliance issues 1. Hart, et al, Meta-analysis pts, Ann Intern Med. 2007;146: Gladstone et al, Stroke, 2009; 40: Waldo AL, et al. J AM Coll Cardiol 2005;46: Holmes at ACC & i2 Summit Wikipedia. Warfarin. Accessed November 1, 2011.
5 CI and reasons for not initiating Warfarin Contraindicated patients 1 : 40% increased risk of stroke 26% increased risk of mortality Physician's Perceived Reasons for Not Initiating Warfarin Therapy 2 Fall Risk 20% Gastrointestinal Bleed 29% Not documented 22% Transient / Secondary AF 22% 1. Hart, et al., Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation; Ann Intern Med. 2007;146: Srivastava, et al. Examining warfarin underutilization rates in patients with atrial fibrillation: Detailed chart review essential to capture contraindications to warfarin therapy; Thrombosis Journal 2008, 6:6doi: /
6 Wallentin, et al., Efficacy and safety of Dabigatran compared with Warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial; The Lancet, 2010: 376; Country distribution of mean time in therapeutic range in the RE-LY trial 5791 Patients on warfarin A large proportion of patients were outside the therapeutic range Major variations between countries Europe: about 3 out of 10 patients out of therapeutic range Sweden: 23% out of range Taiwan: 56%
7 In AF, 91% of the thrombi formed in the LA appendage. Rationale for excluding the LAA from the circulation 80 % reduction in stroke > LAA surgical occlusion Garcia-Fernandez et al.: Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: a transesophageal echocardiographic study. J Am Med Assoc 2003, 42: Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61:755 9.
8 LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage Occlusion Procedure
9 PROTECT-AF: Overview Can the WATCHMAN device replace Warfarin? Efficacy Endpoint: Stroke CV death (& Unknown) Systemic embolism Safety Endpoint Non-inferiority & Superiority Bayesian Sequential Design Analysis at 600 pt-yrs & every 150 pt-yrs thereafter 1500 pt-yr Warfarin Non-Valvular AF CHADs 1 Randomization (1:2) Follow-Up: 5 Years Watchman Anticoagulation Regimen Implant to 6 weeks Warfarin (INR 2-3) for 6 weeks Aspirin ( mg) 6 weeks to 6 months Clopidogrel (75 mg) Aspirin ( mg) After 6 months Aspirin ( mg)
10 PROTECT-AF: Inclusion/Exclusion Inclusion: Paroxysmal / Persistent / Permanent AF CHADS 1 (CHF, HTN, 75 yr, Diabetes, TIA/CVA) Eligible for long-term Warfarin therapy Exclusion Mechanical valve or long-term Warfarin needed Contraindication to Warfarin TEE exclusion: anatomy, atheroma, MV stenosis, tumor Symptomatic Carotid disease LVEF < 30% ASD / Atrial septal repair or closure device CV/Ablation planned within 30 days Unable to take ASA / Plavix
11 PROTECT-AF: Patient Demographics
12 PROTECT-AF: Primary Efficacy Endpoint Events include Stroke (ischemic and hemorrhagic), Systemic embolization, CV death
13 PROTECT-AF: Primary Efficacy Endpoint Events include Stroke (ischemic and hemorrhagic), Systemic embolization, CV death 1 2 3
14 Intention-to-Treat: All-Cause Mortality Hazard Ratio with Watchman, 0.66 (95% CI, ) P =
15
16 PROTECT AF: Primary Safety Endpoint
17 Primary Safety Endpoint: Components of the Safety Endpoint Pericardial Tamponade 22 requiring Tx (4.8% of patients) 15 treated percutaneously 7 underwent surgical intervention Extended hospitalization No Death or Long-term Disability Effect of operator experience 1st Half of Cohort: 6.3% 2nd Half of Cohort: 3.7% Early = First 7 days Late = After 7 days
18 LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail, Amplatzer. Left Atrial Appendage Occlusion Procedure
19 Characteristic PROTECT AF N=463 CAP N=566 PREVAIL N=269 P value Age, years 71.7 ± 8.8 (463) (46.0, 95.0) 74.0 ± 8.3 (566) (44.0, 94.0) 74.0 ± 7.4 (269) (50.0, 94.0) <0.001 Gender (Male) 326/463 (70.4%) 371/566 (65.5%) 182/269 (67.7%) CHADS 2 Score (Continuous) CHADS 2 Risk Factors 2.2 ± 1.2 (1.0, 6.0) 2.5 ± 1.2 (1.0, 6.0) 2.6 ± 1.0 (1.0, 6.0) CHF 124/463 (26.8%) 108/566 (19.1%) 63/269 (23.4%) Hypertension 415/463 (89.6%) 503/566 (88.9%) 238/269 (88.5%) Age /463 (41.0%) 293/566 (51.8%) 140/269 (52.0%) Diabetes 113/463 (24.4%) 141/566 (24.9%) 91/269 (33.8%) Stroke/TIA 82/463 (17.7%) 172/566 (30.4%) 74/269 (27.5%) <0.001 Most notable differences: Age, Diabetes, and Prior Stroke/TIA PROTECT AF and CAP data, from Reddy, VY et al. Circulation. 2011;123:
20 Procedure Implant Success CAP Implant success PREVAIL Implant success 95,1% PROTECT AF Implant success 94,3% 90.9% Implant success defined as deployment and release of the device into the left atrial appendage p = 0.04 PROTECT AF and CAP data from Reddy, VY et al. Circulation. 2011;123:
21 7 Day Procedure/Device Related Vascular complications Cardiac perforation, pericardial effusion with tamponade, ischemic stroke, device embolization, and other vascular complications 1 10,0% 8,0% 8.7% p = % of Patients 6,0% 4,0% 2,0% 0,0% 4.1% 4,4% n=39 n=23 n=12 PROTECT AF CAP PREVAIL No procedure-related deaths reported in any of the trials PROTECT-AF and CAP data from Reddy, VY et al. Circulation. 2011;123: Includes observed PE not necessitating intervention, AV fistula, major bleeding requiring transfusion, pseudoaneurysm, hematoma and groin bleeding
22 At 18 months, the rate of the first coprimary efficacy endpoint (composite of stroke, systemic embolism [SE], and cardiovascular/unexplained death) was in the device group versus in the control group (rate ratio 1.07 [95% credible interval (CrI): 0.57 to 1.89]) and did not achieve the prespecified criteria noninferiority (upper boundary of 95% CrI $1.75).
23 The rate for the second coprimary efficacy endpoint (stroke or SE >7 days postrandomization) was versus , achieving noninferiority
24 ASAP Registry, N=142 1 st EP: Occurrence of stroke (ischemic and hemorrhagic), CV death (cardiovascular and unexplained), system embolism Inclusion Criteria Paroxysmal, persistent or permanent non-valvular AF CHADS 2 score 1 Contraindication for Warfarin Exclusion Criteria ECHO: LVEF <30%, Intracardiac thrombi, Complex aortic atheroma, High-Risk PFO (Aneurysm >15mm or Length 15mm) Symptomatic Carotid disease History of stroke/tia (within last 30 days)
25 ASAP Registry Efficacy Outcome 77% Reduction 8,0% 7,0% 6,0% 7,3% Mean CHADS 2 Score = 2.8 ± 1.2 5,0% 4,0% 3,0% 2,0% 1,0% 1,7% Expected, based on CHADS2 Score Observed rate in ASAP 0,0% 1 Efficacy outcome: Occurrence of stroke (ischemic and hemorrhagic), CV death (cardiovascular and unexplained), system embolism
26 The Amplatzer Cardiac Plug Experience 974 Pts, 20 Sites, Europe and Canada
27 Indication for LAAO
28 Amplatzer Cardiac Plug Experience Success rate and complications
29 Amplatzer Cardiac Plug Experience: The Efficacy
30
31
32
33 LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage Occlusion Procedure
34 LAA Occlusion: Percutaneous, Transcatheter, Transseptal approach Barbs Engage LAA Wall 160 µ PET fabric Watchman AMPLATZER Cardiac Plug self-expanding nitinol frame with fixation anchors and a permeable fabric cover
35
36
37
38
39
40
41
42
43 TEE at 6 Weeks FU
44
45 LAA Occlusion: Summary LAA is critical to the pathogenesis of stroke (91%) Local therapy (LAAO) is to Warfarin 40% reduction of stroke, systemic embolism, CV death Efficacy preserved in pts at highest risk (prior stroke/tia) Procedural risks: Tamponade, Migration, Bleeding.. Learning Curve: 2.2% (CAP Registry), 1.9% (PREVAIL) Indications:. non valvular AF + CI to ACT + CHA2DS2-VASc 4,. Decrease in TE events > Procedural risks
Patients selection criteria for LAA occlusion. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Patients selection criteria for LAA occlusion Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Atrial Fibrillation The most common cardiac arrhythmia. Confers
More informationAppendage Closure. Jason Rogers, MD. Director, Interventional Cardiology UC Davis Medical Center Sacramento, California
Appendage Closure Jason Rogers, MD Director, Interventional Cardiology UC Davis Medical Center Sacramento, California Left Atrium: Atrial Fibrillation Left Atrial Appendage Left Atrium Incidence of Atrial
More informationWatchman. Left Atrial Appendage Closure Device. Uniquely engineered for the LAA 1-3 with proven safety and longterm efficacy. 4-8
TM Watchman Left Atrial Appendage Closure Device PROOF OFLEADERSHIP Uniquely engineered for the LAA 1-3 with proven safety and longterm efficacy. 4-8 Patients with AF have a 5x increased risk of stroke.
More informationTHINK OUTSIDE THE PILLBOX
WATCHMAN : A CLINICALLY PROVEN AND SAFE THERAPY FOR YOUR NVAF PATIENTS WATCHMAN reduces the risk of stroke in NVAF patients as effectively as warfarin WATCHMAN also reduces the long-term risk of bleeding
More informationLeft Atrial Appendage Occlusion
Left Atrial Appendage Occlusion A new strategy to prevent stroke in atrial fibrillation Ashok Talreja MD and Arijit Chanda MD VHVI symposium 24th February 2018 Outline of presentation 1. Risk of stroke
More informationWatchman a Stroke Prevention Technology for Patients with Atrial Fibrillation
Watchman a Stroke Prevention Technology for Patients with Atrial Fibrillation Scripps hospital,la Jolla, CA Atrial fibrillation is a major source of cardiogenic embolic related stroke 500,000 strokes per
More informationTechnique, Risk, and Benefit. T. Santoso University of Indonesia Medical School,
Left Atrial Appendage Closure Technique, Risk, and Benefit T. Santoso University of Indonesia Medical School, Medistra Hospital, Jakarta, Indonesia Percutaneous LAA Closure Devices PLAATO (no longerdeveloped)
More informationDevices to Protect Against Stroke in Atrial Fibrillation
Devices to Protect Against Stroke in Atrial Fibrillation Jonathan C. Hsu, MD, MAS Associate Clinical Professor Division of Cardiology, Section of Cardiac Electrophysiology June 2, 2018 Disclosures Honoraria
More informationLeft Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016
Left Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016 Jesse Jorgensen, MD, FACC Director, Cardiac Cath Lab, Greenville Health System Disclosures
More informationLeft Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation
Left Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation Zoltan G. Turi, M.D. Rutgers Robert Wood Johnson Medical School New Brunswick, NJ Disclosure Information Zoltan G.
More informationLeft Atrial Appendage Closure
Left Atrial Appendage Closure Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org Risk Factors for Stroke From The Perspective
More informationLeft Atrial Appendage Closure 4 questions Who? When? How? Results?
Left Atrial Appendage Closure 4 questions Who? When? How? Results? David R. Holmes, Jr., M.D. Mayo Clinic, Rochester ACC New York CVS New York, NY December 2017 2012 MFMER slide-1 Presenter Disclosure
More informationPercutaneous Left Atrial appendage occlusion and anticoagulation therapy Nicolas Lellouche, MD, PhD
Percutaneous Left Atrial appendage occlusion and anticoagulation therapy Nicolas Lellouche, MD, PhD Fédération de Cardiologie Hôpital Henri Mondor Créteil Atrial Fibrillation is a major cause of Stroke
More informationLeft Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE
Left Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE Adam Greenbaum, MD NCVH Detroit 2015-09-12 Disclosures Former proctor: SentreHEART Discussion may include the use of non-fda approved devices
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationPage 1. Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion. Atrial fibrillation: Scope of the problem
Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion Benjamin A. D Souza, MD, FACC, FHRS Assistant Professor of Clinical Medicine Penn Presbyterian Medical Center Cardiac
More informationWATCHMAN: Where do we stand
Latest Updated on LAAC and Its Clinical Evidence Saibal Kar, MD, FACC, FAHA, FSCAI Associate Professor Heart Institute, t Cedars Sinai i Medical Center, Los Angeles, CA Disclosure Information WATCHMAN:
More informationLeft Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD
Left Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD Director of Interventional Cardiac Research Cedars Sinai Medical Center Disclosure Statement
More informationWilliam A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, Pennsylvania USA
William A. Gray MD System Chief of Cardiovascular Services, President, Wynnewood, Pennsylvania USA What does Guilty until Effective mean? A fact is a simple statement that everyone believes. It is innocent
More informationTrick or Treat 2: A New Era of Stroke Prevention in AF? WATCHMAN and LARIAT?
Trick or Treat 2: A New Era of Stroke Prevention in AF? WATCHMAN and LARIAT? Disclosure SentreHeart, Inc Consultant Equity holder A cardiac disease that kills by producing emboli The most severe consequence
More informationRole of cardiac imaging for catheterbased left atrial appendage closure
Role of cardiac imaging for catheterbased left atrial appendage closure Ana G. Almeida, MD, PhD Cardiology University Hospital Santa Maria, Lisbon Ana G. Almeida, MD, PhD, FESC University Hospital Santa
More informationPREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation
PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation Dr. Saibal Kar, MD TCT 2017 Late Breaking Clinical
More informationLeft Atrial Appendage Closure in SCRIPPS CLINIC
Left Atrial Appendage Closure in Atrial Fibrillation to Prevent Stroke Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org
More informationLeft-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Medical Policy Manual Surgery, Policy No. 195 Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Next Review: November 2019 Last Review: January 2019 Effective: February
More informationEndocardial LAA Occlusion: Which Device for Which Patient?
Endocardial LAA Occlusion: Which Device for Which Patient? Roy Beinart, MD Davidai Arrhythmia Center The Leviev Heart Center Sheba Medical Center Sheba Medical Center Tel Hashomer The Leviev Heart Center
More informationLeft Atrial Appendage Closure Devices. Atrial Fibrillation 10/11/2017
Left Atrial Appendage Closure Devices Emile Daoud, MD Chief, Cardiac Electrophysiology Wexner Medical Center, The Ohio State University Atrial Fibrillation 1 Adjusted Annual Stroke Risk Using CHA 2 DS
More informationTHINK OUTSIDE THE PILLBOX
THINK OUTSIDE THE PILLBOX An innovative one-time procedure that reduces the risk of stroke in your non-valvular atrial fibrillation (NVAF) patients and the long-term risk of bleeding that comes with a
More informationUpdate in Left Atrial Appendage Occlusion: More Options
Update in Left Atrial Appendage Occlusion: More Options Sajjad A Sabir, MD Director, Structural Heart Disease Program Director, Interventional Echocardiography Director, Heart Valve Clinic Non-Valvular
More informationLeft Atrial Appendage Occlusion in the Era of Novel Anticoagulants
Left Atrial Appendage Occlusion in the Era of Novel Anticoagulants Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac Research Heart Institute, Cedars-Sinai Medical Center,
More informationLeft atrial appendage occlusion
Kardiologie Left atrial appendage occlusion Mischa Kühne Kardiolunch, 10.9.2015 Overall stroke rate 5% per year CHA 2 DS 2 VASC score Most AF patients need protection from stroke ESC guidelines AF, 2010/2012
More informationDad needed to get off his blood thinner. His doctor told us about an alternative. It s called
Dad needed to get off his blood thinner. His doctor told us about an alternative. It s called A one-time procedure that may reduce stroke risk for a lifetime in people with AFib not caused by a heart valve
More informationDisappearing LAA Thrombus Resulting in Stroke Parekh A, Parekh Ezekowitz M et al: Circ 1 Ezekowitz 14:e513, 2006 M et al: Circ 1
LAA Ablation for Atrial Fibrillation Saudi Heart ACC Riyadh, Saudi Arabia February 2011 David R. Holmes, MD Mayo Clinic Rochester, MN Presenter Disclosure Information David R. Holmes, Jr., M.D. LAA Ablation
More informationTHINK OUTSIDE THE PILLBOX
THINK OUTSIDE THE PILLBOX An innovative one-time procedure that reduces the risk of stroke in your non-valvular atrial fibrillation (NVAF) patients and the long-term risk of bleeding that comes with a
More informationAbstract 1 INTRODUCTION ORIGINAL ARTICLE
Received: 5 October 2017 Revised: 2 November 2017 Accepted: 6 November 2017 DOI: 10.1111/jce.13385 ORIGINAL ARTICLE Feasibility of percutaneous left atrial appendage closure using a novel LAmbre occluder
More informationDevices for Stroke Prevention. Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP
Devices for Stroke Prevention Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP Overview Left Atrial Appendage Closure FDA Approved Watchman Investigational Amulet PFO Closure Atrial Fibrillation
More informationLeft atrium appendage closure: A new technique for patients at high hemorrhagic risk
Left atrium appendage closure: A new technique for patients at high hemorrhagic risk Victoria Martin Yuste MD PhD ITC. Cardiology Department. Hospital Clinic. Barcelona SITE. Barcelona, Juin-9-2013 NON
More informationAtrial fibrillation (AF) affects approximately 33 million
Emerging Options for Anticoagulation in LAA Closure Managing anticoagulation and antiplatelet therapy in patients undergoing percutaneous left atrial appendage closure with the Watchman device. BY JESSICA
More information16th ANGIOPLASTY SUMMIT-TCTAP TCTAP 2011 Seoul, Korea, April 27 29, 2011 Left Atrial Appendage Closure State of the Art Horst Sievert, Nina Wunderlich, Maik Gonzaga, Annkathrin Braut, Ilona Hofmann CardioVascular
More informationLeft Atrial Appendage Closure: Techniques and Guidelines. Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA
Left Atrial Appendage Closure: Techniques and Guidelines Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA May is Stroke Awareness Month 2 September is AF Awareness Month Lecture Highlights
More informationSHARED DECISION MAKING: AN EVIDENCE-BASED CORNERSTONE OF LAAC THERAPY
SHARED DECISION MAKING: AN EVIDENCE-BASED CORNERSTONE OF LAAC THERAPY SHARED DECISION MAKING: AN EVIDENCE BASED CORNERSTONE OF LAAC THERAPY Shared decision making is a collaborative process that allows
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Percutaneous Left Atrial Appendage Closure Device Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Percutaneous Left Atrial Appendage Closure Devices
More informationCryptogenic Stroke: A logical approach to a common clinical problem
Cryptogenic Stroke: A logical approach to a common clinical problem Alphonse M. Ambrosia, DO, FACC Interventional Cardiologist CardioVascular Associates of Mesa Mesa, Arizona Speakers Bureau Boston Scientific
More informationPERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES
PERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES Dr.Vinny K.Ram No disclosures TAVR 1 Lesson number 1:
More informationWatchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg
Watchman and Structural update..the next frontier Ari Chanda, MD Cardiology Associates of Fredericksburg Different Left Atrial Appendage (LAA) morphologies Watchman (the device) Fabric Anchors Device structure
More informationLeft Atrial Appendage Closure Techniques: 2015
Left Atrial Appendage Closure Techniques: 2015 Ramon Quesada, MD, FACP, FACC, FSCAI Medical Director, Interventional Cardiology & Cardiac Research Medical Director, Structural Heart and TAVR Program Baptist
More informationUpdate in the Management of Atrial Fibrillation
Update in the Management of Atrial Fibrillation Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisco Disclosures Research: Gilead, Medtronic,
More informationPercutane structurele interventies. Hartoor sluiting (Watchman )
Percutane structurele interventies Dr. Luc Muyldermans Dr. Yves Vandekerckhove Dr. Luc Missault Dr. Daniël Dendooven Dr. Patrick Coussement Prof. Mattias Duytschaever Prof. René Tavernier Dr. Philippe
More informationPrimary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion. Greg Francisco, MD, FACC
Primary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion Greg Francisco, MD, FACC DISCLOSURES None to declare Estimated 33.5million have AF worldwide (6-7million in
More informationRate or Rhythm Control? Epidemiology. Relevant Advances in Atrial Fibrillation 6/20/2011. Stroke Prophylaxis
Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Managing Atrial Fibrillation: Tips for the Generalist Antiarrhythmic Drug Therapy Ablation Gregory M Marcus, MD, MAS Assistant Professor of Medicine
More informationWhat the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen
What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen What the cardiologist should know about arrhythmia and stroke are there real low
More informationModern aspects in multidisciplinary thromboembolic prophylaxis. AMPLATZER Left Atrial Appendage data update
Modern aspects in multidisciplinary thromboembolic prophylaxis AMPLATZER Left Atrial Appendage data update Igal Moarof, MD Interventional Cardiology Kantonsspital Aarau Potential conflicts of interest
More informationLEFT ATRIAL APPENDAGE CLOSURE INSTEAD OF ANTICOAGULATION; INDICATIONS AND OUTCOMES. Sheetal Chandhok, MD
LEFT ATRIAL APPENDAGE CLOSURE INSTEAD OF ANTICOAGULATION; INDICATIONS AND OUTCOMES Sheetal Chandhok, MD Disclosures Boston Scientific: Speaker (Watchman) Trainer (Watchman) SentreHeart Primary Investigator
More informationCARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Title: Reintroduction Overview: Watchman Speaker: Mario Goessl, MD, FACC, FAHA, FESC, FSCAI Minneapolis Heart Institute at Abbott Northwestern Hospital Date: Monday, October 24,
More informationNCVH Birmingham 2013 August 24, Michael S. Bailey, MD Birmingham Heart Clinic
NCVH Birmingham 2013 August 24, 2013 Michael S. Bailey, MD Birmingham Heart Clinic NCVH Birmingham 2015 August 29, 2015 Michael S. Bailey, MD Birmingham Heart Clinic Left Atrial Anatomy Part of a larger
More informationAtrial fibrillation (AF), one of the
Hellenic J Cardiol 2013; 54: 408-412 Case Report Left Atrial Appendage Occlusion with the Amplatzer Amulet for Stroke Prevention in Atrial Fibrillation: The First Case in Greece Apostolos Tzikas, Lambros
More informationWATCHMAN PROTECT AF Study Rev. 6
WATCHMAN PROTECT AF Study Rev. 6 Protocol Synopsis Title WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation (PROTECT AF) Sponsor Atritech/Boston Scientific
More informationChapter 76 Left Atrial Appendage Closure: Indication and Technique
Chapter 76 Left Atrial Appendage Closure: Indication and Technique RANJAN SHETTY INTRODUCTION Atrial fibrillation (AF) is one of the most common cardiac arrhythmias, which affects around 3% 5% of the population
More informationLAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC
LAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC INTERVENTIONAL CARDIOLOGIST DIRECTOR, ADULT CARDIOLOGY FELLOWSHIP TRAINING
More informationLeft Atrial Appendage Closure: The Rationale
Left Atrial Appendage Closure: The Rationale JOHN D. HUMMEL, MD DIRECTOR OF CLINCAL ELECTROPHYSIOLOGY RESEARCH PROFESSOR OF CLINICAL INTERNAL MEDICINE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER 1 Disclosures
More informationICE 2012 Ioannina,
ICE 2012 Ioannina, 15-12-2012 Case presentation Left Atrial Appendage Occlusion therapy for Stroke Prevention in Atrial Fibrillation Apostolos Tzikas MD, PhD, FESC Interventional Cardiology Congenital
More information8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes
8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference 2017 Dubai: 19-21 October 2017 Acute Coronary Syndromes Antonio Colombo Centro Cuore Columbus and S. Raffaele Scientific
More informationRole of Imaging in Complex LAA Closure Anatomies
Role of Imaging in Complex LAA Closure Anatomies Sameer Gafoor 1,2 1 Swedish Heart and Vascular: Ming Zhang, Paul Huang, Darryl Wells, Adam Zivin, John Petersen II, Madalena Petrescu, Nimish Muni, Eric
More informationMEDICAL POLICY MEDICAL POLICY DETAILS POLICY STATEMENT POLICY GUIDELINES DESCRIPTION. Page: 1 of 9
Page: 1 of 9 MEDICAL POLICY MEDICAL POLICY DETAILS Medical Policy Title PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE DEVICES Policy Number 7.01.92 Category Technology assessment Effective Date 08/20/15 Revised
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationTREATMENT OF STROKE PATIENTS THAT ARE TAKING NOVEL ANTICOAGULANTS. Jesse Weinberger, MD The Icahn School of Medicine at Mount Sinai
TREATMENT OF STROKE PATIENTS THAT ARE TAKING NOVEL ANTICOAGULANTS Jesse Weinberger, MD The Icahn School of Medicine at Mount Sinai Acknowledgement Many of the slides for this presentation were obtained
More informationIs there a role for transcatheter left atrial appendage occlusion?
REVIEW Review Is there a role for transcatheter left atrial appendage occlusion? For patients with atrial fibrillation, successful warfarin therapy is difficult in clinical practice. Thus, it seems logical
More informationATRIAL SEPTAL CLOSURE AND LEFT ATRIAL APPENDAGE OCCLUSION: INDICATIONS AND GUIDANCE ECHOCARDIOGRAPHY IN INTERVENTIONAL CARDIOLOGY
ATRIAL SEPTAL CLOSURE AND LEFT ATRIAL APPENDAGE OCCLUSION: INDICATIONS AND GUIDANCE Aristides G. Panlilio, MD, FPCP, FPCC,FPSE, FASE Philippine Heart Center Chinese General Hospital and Medical Center
More informationMEDICAL POLICY SUBJECT: PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE DEVICES EFFECTIVE DATE: 08/20/15 REVISED DATE: 10/20/16, 11/16/17
MEDICAL POLICY SUBJECT: PERCUTANEOUS LEFT ATRIAL CATEGORY: Technology assessment PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.
More informationPercutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Policy Number: 2.02.26 Last Review: 6/2014 Origination: 1/2012 Next Review: 12/2014 Policy Blue Cross and
More informationAntithrombotic Efficacy and Safety of Dabigatran Etexilate
130419 Luncheon Symposium_2013 춘계심장학회 Antithrombotic Efficacy and Safety of Dabigatran Etexilate Hui-Nam Pak, MD, PhD. Division of Cardiology Yonsei University Health System Atrial Fibrillation Risk of
More informationLeft Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation
Left Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation Issam D. Moussa, MD Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Medicine
More informationAntithrombotic Therapy in Patients with Atrial Fibrillation
Antithrombotic Therapy in Patients with Atrial Fibrillation June Soo Kim, M.D., Ph.D. Department of Medicine Cardiac & Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine
More informationTITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations
TITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations DATE: 29 September 2010 CONTEXT AND POLICY ISSUES: Atrial fibrillation (AF) is the irregular, rapid beating of the
More informationPercutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Policy Number: 2.02.26 Last Review: 12/2018 Origination: 1/2012 Next Review: 12/2019 Policy Blue Cross and
More informationRelevant Advances in Atrial Fibrillation
Gregory M Marcus, MD, MAS Assistant Professor of Medicine Division of Cardiology University of California, San Francisco Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Antiarrhythmic Drug
More informationLive in a Box: Left Atrial Appendage Closure Device
Live in a Box: Left Atrial Appendage Closure Device Fayez Bokhari, MD, FRCPC KFAFH, Jeddah Saudi Arabia Joint Saudi Heart Association/SACIS April 18, 2015 News: Interventional Cardiologists harm patients
More informationContinuing Cardiology Education
Continuing Cardiology Education REVIEW ARTICLE Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: indications diversity and future perspectives A. Tzikas 1 & T.
More informationGauging stroke risk across the AF spectrum and selecting the appropriate patient for LAA closure. Miguel Valderrábano, MD
Gauging stroke risk across the AF spectrum and selecting the appropriate patient for LAA closure Miguel Valderrábano, MD Risk of Stroke in Atrial Fibrillation CHADS 2 -CHA 2 DS 2 -VASc Scores Adjusted
More informationNON SURGICAL TREATMENT OF CARDIAC DISEASE PETER J SABIA, MD FACC ASSOCIATES IN CARDIOLOGY SILVER SPRING, MARYLAND
NON SURGICAL TREATMENT OF CARDIAC DISEASE PETER J SABIA, MD FACC ASSOCIATES IN CARDIOLOGY SILVER SPRING, MARYLAND TOPICS ATRIAL SEPTAL DEFECT VSD IHSS PERCUTANEOUS AORTIC VALVE PERCUTANEOUS MITRAL VALVE
More informationEP Clinical Research Program Summary. Daniel L Lustgarten MD PhD Associate Professor The University of Vermont School of Medicine
EP Clinical Research Program Summary Daniel L Lustgarten MD PhD Associate Professor The University of Vermont School of Medicine Financial Disclosures Consultant and/or Research Support: Medtronic Biosense
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More information[N] = No product variation, policy applies as stated [Y] = Standard product coverage varies from application of this policy, see below
Original Issue Date (Created): July 26, 2011 Most Recent Review Date (Revised): November 26, 2013 Effective Date: February 1, 2014 I. POLICY The use of percutaneous left-atrial appendage closure devices
More information심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation
소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE
More informationWatchman Implantation Case Presentation and Discussion
Watchman Implantation Case Presentation and Discussion Walid Saliba, MD, FHRS Director Atrial Fibrillation Center Co-Director AF Stroke Prevention Center Cleveland Clinic Indication FDA NonValvular AF
More informationAtrial Fibrillation. Atrial Fibrillation
Atrial Fibrillation Stroke and Blood Thinning Medications What else is available? Srinivas Iyengar, MD, FACC, with Boulder Heart Structural Heart Director, Boulder Community Health 303-622-5849 Atrial
More informationTechnology Assessment Report No. 302
Technology Assessment Report No. 302 Economic Analysis of Left Atrial Appendage Closure for patients with atrial fibrillation, high stroke risk, and contraindicated to anticoagulants Last updated May 2018
More informationManuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
More informationUpdate in Left Atrial Appendage Closure Devices. Faisal Al-Samadi MBBS, FRCPC, FACP, FACC, FSCAI, FHRS
Update in Left Atrial Appendage Closure Devices Faisal Al-Samadi MBBS, FRCPC, FACP, FACC, FSCAI, FHRS Atrial Fibrillation - Overview Higher stroke risk for older patients and those with prior stroke or
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationLeft atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives
Review Article Left atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives Bin Kong 1,2, Yu Liu 1,2, He Huang 1,2, Hong Jiang 1,2, Congxin
More informationIntracardiac Devices for Stroke Prevention: The Heart Brain Team
Intracardiac Devices for Stroke Prevention: The Heart Brain Team CREIGHTON W. DON, MD, PHD ASSOCIATE PROFESSOR OF MEDICINE DIRECTOR, INTERVENTIONAL AND STRUCTURAL HEART FELLOWSHIPS DIVISION OF CARDIOLOGY
More informationAtrial fibrillation (AF) is the most common
Left Atrial Appendage Closure With the Watchman Device A review of trial results and clinical application. BY JAYANT KHITHA, MD, AND TANVIR K. BAJWA, MD Atrial fibrillation (AF) is the most common arrhythmia
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationCombined catheter ablation and left atrial appendage closure as a. treatment of atrial fibrillation
Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrial fibrillation Giulio Molon, MD FACC, FESC, Fellow ANMCO Card Dept, S.Cuore hospital Negrar
More informationAtrial fibrillation and advanced age
Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients
More informationLeft Atrial Appendage Closure: Neurological events
Left Atrial Appendage Closure: Neurological events Medical Director- Foundation for Cardiovascular Medicine San Diego, CA Director Advanced Interventional Therapies- Gagnon Cardiovascular Institute, Morristown,
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationSafety and efficacy results in the EWOLUTION all-comers LAA closure study: DAPT subgroup
Safety and efficacy results in the EWOLUTION all-comers LAA closure study: DAPT subgroup Martin W. Bergmann, Hüseyin Ince, Stephan Kische, Thomas Schmitz, Felix Meincke, Boris Schmidt, David Foley, Timothy
More informationMedical Policy Manual. Topic: Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation. Date of Origin: December 2011
Medical Policy Manual Topic: Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Date of Origin: December 2011 Section: Medicine Last Reviewed Date: October 2013 Policy No:
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More information